

PUBLIC EXPOSE PT Darya-Varia Laboratoria Tbk Mulia Hotel, 25 May 2016



Agenda

- 1. Indonesia Economy
- 2. Pharma Industry
- 3. DVL Profile
- 4. DVL Business Overview
- 5. Performance 1st Q 2016




1. INDONESIA ECONOMY






Indonesia Economy Indicator

Indonesia GDP growth slightly improved in Q4 2015 and actual inflation for 12 months in 2015 was relatively low at 3.4%





BI Rate (%)




Sources: Bank of Indonesia and BPS



Indonesia GDP

Both Government Spending and Investment showed improvement. Yet, Household Consumptions growth was slowing down.



Source: BPS



۲

Consumer Confidence - BI



CEI : Consumer Expectation Index

•

Source: Indeks Kepercayaan Konsumen Bank Indonesia







Pharmaceutical Industry Growth

	MAT 1Q2016		1Q2016	
	%S	% G	%S	% G
TOTAL MARKET	100.0%	3.4%	100.0%	2.4%
ETHICAL	61.8%	5.6%	61.1%	3.8%
отс	38.2%	0.0%	38.9%	0.3%
DOMESTIC COMPANIES	72.2%	2.1%	72.0%	3.4%
MULTINATIONAL COMPANIES	27.8%	6.8%	28.0%	0.1%
BRANDED	88.2%	2.3%	89.1%	1.1%
UNBRANDED	11.8%	12.4%	10.9%	14.4%

Total market grew by 2.4%, mainly driven by generics, while OTC was stagnant

Source: IMS Health 1Q -2016



3. DVL COMPANY PROFILE



Main Business Streams

1. Bisnis Obat Resep/Prescription Business



2. Bisnis Consumer Health/Consumer Health Business



3. Bisnis Ekspor dan *Toll Manufacturing/Export and Toll Manufacturing Business*





Production Facilities



Citeureup, Bogor (Sterile & Solid)

Gunung Putri, Bogor (Soft Capsule, Liquid, Cosmetic)



4. DVL HIGHLIGHTS





New Product Launch

Prescription





New Product Launch

Consumer Health



Natur-E Advanced Skin supplement with Vitamin E, Astaxanthin & Lycopene



Communication Program Consumer Health





Communication Program





Communication Program





5. DVL Performance



DVL Performance

Performance 2015	Sales	Growth
	(BIDR)	
Prescription Business	580	3%
Consumer Health Business	435	41%
Total Product Sales	1,015	22%
Toll/ Export Business	292	25%
Total Gross Sales	1,307	23%



DVL Performance

Performance Q1 - 2016	Sales	Growth
	(BIDR)	
Prescription Business	136	10.7%
Consumer Health Business	166	13.3%
Total Product Sales	302	12.1%
Toll/ Export Business	77	5.9%
Total Gross Sales	379	10.8%



End Presentation